FDA 2022 Study Warns Against High Risk, High Traffic Fever Screening
FDA scientists published a new fever camera study which found strong performance when strict standards are maintained. However, the study warned about high risk, high traffic screening and did not test the devices or screening methods seen in real world use during the Covid-19 pandemic.
Inside this report, we examine what the study found, and what it says about fever cameras used during the pandemic.
*** *** ************* *** *********** ** * ******* cameras - *.*.*. ******** ************ (****) - ** **** **** **** ***** subjects. *** **** ****** "****** ********* for ********* ******** **** ************" ***** "may ** ****** ** ******** ******** and ****** ********** ******* *********."
"Little ********" ** ****** ** **** *********
*******, *** ***** **** **** ** past ********* "***** ** ****** ******** that **** ******** [** ***** ****] has **** * *********** ******," ******* because ** ***-******* *******, "*********** **********", and **** ********* **********:
** ******* ****** *********, ***** ********* has **** **** ** ****-******* ***** and ** *** ********* ** ****-**** sites, **** ** ****** ************** ****, hospitals, *** ******** ****** **********, ***there ** ****** ******** **** **** ******** *** **** * *********** ******. This may be due ** **** ** *** ************** ** *********** *************** *** *********** **********, ** **** ** * **** ** ******, ************ ******* ******** ********** *** ********** *** *********. [emphasis added]
**** *****, "*** *** ************* *** also ** ************ ** **** ** the *** ** **** **** ************ performance **************."
******** *** ******* **** "*********", *** study ********** **** *** **** ** "according ** ************ **** *********." ** the ***** ******, **** "******* ******* to ************* *********" ******** ***** ***** ********* **********.
******** ****** ****** ****** ****** *** Covid-19 ********, *** ***-********* ********* ********** *** deployment **** *******, *** ******* ************** ****** ** **** *******.
* ********* *******,************************ ********* *** ********** ** ***** was * ***** ********* ** ************* standards. ***** ************* **** ** ***********(*** ********* ******* *** ******* ********* *** months).
*** ***** **** **** *** ****-******* thermal ******* **** **** ****** ********** than **** ******* **** **** ****** the ********: *** **** ******, **** a *** × *** ***** ******, and *** ******** ******* ***. **** P-series **** * *** × *** pixel ****** (**** *** ***(*) *******).
** **********, *** ******* ****** *** terminal, ***** *** ******* ******* *** "found ** **** **** **% ** NFL ********", *** * *** * 90 ******, ** >* ***** ***** pixels **** *** **** ******. ** some ******* ******, *************** ** ** ***** ** * x * ******.
**** ******* ******** **** **** **** compensating ********** **** **** ************ **** clinical ***. ** ***** ****, **** published* ****-******** ******** ************ **** ********** *********** ************.
Testing **********
*** ***** ****** ****** ***********, **** IRTs **** ********* *** ******** ** non-contact ******** ************ (*****) **** ** the ***** *** **********:
**** ******** *** ****** *********** ** IRTs **** ***** ******** **** **** designed *** ******* ***********,the ******** ******** ** **** **** ****** ** ******* **** **** ** *****. The two IRTs have similar accuracy, and both have better bias and precision than the six models of NCITs, even with the worst regression method.
** *** ******, "**** ***** ** a ****** ****** *** ***** ********* in ****-******* ***** ** ******-**** ********* where *** ****** **** ***** ** justified ** ******* *************."
More ******** ********
**** **** "*********" *******, *** ***** acknowledged **** **** **** **** ***** to ** **** ***** ******* ******* are *********** *** ******** ************. “*********, there *** ** ********* ******* ** evaluate *** ******** ******** ** ****.”
*** **** *** ******* ** **** a *** ****** *********** *** ******* others ** ****?
******* ** ****** **** ** ** go ** *** ********* **** ** they **** ******* * *** **** had * ***** ****. * ***** I ***’* ********** **** ********. *** you ****** ** ******* *** * fever **** ****** *** ** ** the ****** ** ********?? **** **** was ***** * *** ********** **** covid *** ******* **** ***** ****** from *****.
****** ***** **** ***** **** **** month *** * **** *** ******* complex ***** * ** **** **** me **** *** "***** ********" ***. They **** ****** ***** ** ** demanding **** **** ***** ****! * even ******* *** *** ********** ** them *** ***** *** *********** *** that *** ***** *** ** *** wrong ********* ** ************* **** **** properly. **** ****** *** **** *** facing *** *******. * **** *** a **** ***** ***'* **** ** I *** * *** ***** *** one ** **** **** * *** below ******!